Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

Insulin Aspart is a rapid-acting type of insulin sold as generic Insulin Aspart and under the brand name Novolog, the ADCES says. Another version of Insulin Aspart, Fiasp, ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Three insulin products are currently in shortage, ... Novo Nordisk is discontinuing Levemir and has a shortage of some Insulin Aspart and Novolog products. Other insulin injections are not in ...

Three insulin products are currently in shortage, but all other insulin products are in good supply, including alternatives for the limited products.